VEGFR-2 as a novel predictor of survival in gastric cancer: A systematic review and meta-analysis

被引：13
作者：
Li, Teng [1 ]
Yu, Jing [1 ]
Luo, Xinyu [1 ]
Ren, Weiguo [2 ]
Zhang, Yue [1 ]
Cao, Bangwei [1 ]
机构：
[1] Capital Med Univ, Beijing Friendship Hosp, Canc Ctr, Beijing 100050, Peoples R China
[2] Beijing Nanyuan Hosp, Dept Endocrinol & Oncol, Beijing 100076, Peoples R China
来源：
PATHOLOGY RESEARCH AND PRACTICE | 2018年 / 214卷 / 04期
关键词：
Gastric cancer; VEGFR-2; Meta-analysis; ENDOTHELIAL GROWTH-FACTOR; CONTROLLED PHASE-III; GASTROESOPHAGEAL JUNCTION; PROGNOSTIC-FACTOR; DOUBLE-BLIND; ADENOCARCINOMA; EXPRESSION; CARCINOMA; CHEMOTHERAPY; RAMUCIRUMAB;
D O I：
10.1016/j.prp.2018.02.005
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
Background Expression of VEGFRs may affect cancer prognosis. The aim of this work is to evaluate the prognostic significance of VEGFRs of patients with gastric cancer. Methods: The databases PubMed, Embase, Web of Science, and Cochrane Library as well as ASCO and ESMO were searched systematically for articles reporting the prognostic significance of tissue VEGFRs in gastric cancer. The statistical analyses were carried out using Stata version 12.0. Results: A total of 8 articles comprising 950 patients were eligible for meta-analysis. The combined HR of studies evaluating total VEGFRs overexpression was 1.42 (95% CI 1.01-2.00, P = 0.044), suggesting that it had prognosis significance in overall survival of gastric cancer. Subgroup analysis showed that it was VEGFR-2 (HR 1.81, 95% CI 1.31-2.49, P < 0.001) but not VEGFR-3 (HR 0.91, 95% CI 0.45-1.82, P = 0.787) overexpression was associated with an increased risk of median overall survival (mOS) and it can be a potentially predictive biomarker for gastric cancer. Conclusions: VEGFR-2 overexpression is a promising negative prognosis predictor for patients with gastric cancer. The prognosis significance of VEGFR-3 still need further study.
引用
收藏
页码：560 / 564
页数：5
相关论文
共 22 条
[1]   Endocan-expressing microvessel density as a prognostic factor for survival in human gastric cancer [J].
Chang, Yuan ;
Niu, Wei ;
Lian, Pei-Long ;
Wang, Xian-Qiang ;
Meng, Zhi-Xin ;
Liu, Yi ;
Zhao, Rui .
WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (23) :5422-5429
[2]   Phosphorylated VEGFR2 and hypertension: potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy [J].
Fan, Minhao ;
Zhang, Jian ;
Wang, Zhonghua ;
Wang, Biyun ;
Zhang, Qunlin ;
Zheng, Chunlei ;
Li, Ting ;
Ni, Chen ;
Wu, Zhenhua ;
Shao, Zhimin ;
Hu, Xichun .
BREAST CANCER RESEARCH AND TREATMENT, 2014, 143 (01) :141-151
[3]   Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab [J].
Fuchs, Charles S. ;
Tabernero, Josep ;
Tomasek, Jiri ;
Chau, Ian ;
Melichar, Bohuslav ;
Safran, Howard ;
Tehfe, Mustapha A. ;
Filip, Dumitru ;
Topuzov, Eldar ;
Schlittler, Luis ;
Udrea, Anghel Adrian ;
Campbell, William ;
Brincat, Stephen ;
Emig, Michael ;
Melemed, Symantha A. ;
Hozak, Rebecca R. ;
Ferry, David ;
Caldwell, C. William ;
Ajani, Jaffer A. .
BRITISH JOURNAL OF CANCER, 2016, 115 (08) :974-982
[4]   Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial [J].
Fuchs, Charles S. ;
Tomasek, Jiri ;
Yong, Cho Jae ;
Dumitru, Filip ;
Passalacqua, Rodolfo ;
Goswami, Chanchal ;
Safran, Howard ;
dos Santos, Lucas Vieira ;
Aprile, Giuseppe ;
Ferry, David R. ;
Melichar, Bohuslav ;
Tehfe, Mustapha ;
Topuzov, Eldar ;
Zalcberg, John Raymond ;
Chau, Ian ;
Campbell, William ;
Sivanandan, Choondal ;
Pikiel, Joanna ;
Koshiji, Minori ;
Hsu, Yanzhi ;
Liepa, Astra M. ;
Gao, Ling ;
Schwartz, Jonathan D. ;
Tabernero, Josep .
LANCET, 2014, 383 (9911) :31-39
[5]   The effect of the expression of vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 on the clinical outcome in patients with gastric carcinoma [J].
Han, F. -H. ;
Li, H. -M. ;
Zheng, D. -H. ;
He, Y. -L. ;
Zhan, W. -H. .
EJSO, 2010, 36 (12) :1172-1179
[6]   Impact of vascular endothelial growth factor receptor 1, 2, and 3 expression on the outcome of patients with gastric cancer [J].
Hirashima, Yoshinori ;
Yamada, Yasuhide ;
Matsubara, Junichi ;
Takahari, Daisuke ;
Okita, Natsuko ;
Takashima, Atsuo ;
Kato, Ken ;
Hamaguchi, Tetsuya ;
Shirao, Kuniaki ;
Shimada, Yasuhiro ;
Taniguchi, Hirokazu ;
Shimoda, Tadakazu .
CANCER SCIENCE, 2009, 100 (02) :310-315
[7]   The prognostic significance of growth factors and growth factor receptors in gastric adenocarcinoma [J].
Kim, Jung Yeon ;
Jeon, Tae Joo ;
Bae, Byung-Noe ;
Kwon, Ji Eun ;
Kim, Hyun-Jung ;
Park, Kyeongmee ;
Shin, Eunah .
APMIS, 2013, 121 (02) :95-104
[8]   Short and long-term survival from gastric cancer. A population-based study from a county hospital during 25 years [J].
Lello, Elisabeth ;
Furnes, Bjorg ;
Edna, Tom-H .
ACTA ONCOLOGICA, 2007, 46 (03) :308-315
[9]   VASCULAR ENDOTHELIAL GROWTH-FACTOR IS A SECRETED ANGIOGENIC MITOGEN [J].
LEUNG, DW ;
CACHIANES, G ;
KUANG, WJ ;
GOEDDEL, DV ;
FERRARA, N .
SCIENCE, 1989, 246 (4935) :1306-1309
[10]   Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction [J].
Li, Jin ;
Qin, Shukui ;
Xu, Jianming ;
Xiong, Jianping ;
Wu, Changping ;
Bai, Yuxian ;
Liu, Wei ;
Tong, Jiandong ;
Liu, Yunpeng ;
Xu, Ruihua ;
Wang, Zhehai ;
Wang, Qiong ;
Ouyang, Xuenong ;
Yang, Yan ;
Ba, Yi ;
Liang, Jun ;
Lin, Xiaoyan ;
Luo, Deyun ;
Zheng, Rongsheng ;
Wang, Xin ;
Sun, Guoping ;
Wang, Liwei ;
Zheng, Leizhen ;
Guo, Hong ;
Wu, Jingbo ;
Xu, Nong ;
Yang, Jianwei ;
Zhang, Honggang ;
Cheng, Ying ;
Wang, Ningju ;
Chen, Lei ;
Fan, Zhining ;
Sun, Piaoyang ;
Yu, Hao .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (13) :1448-+
123